{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:56:58Z","timestamp":1773039418919,"version":"3.50.1"},"reference-count":73,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chang Gung Medical Foundation","award":["CMRPVVM0121"],"award-info":[{"award-number":["CMRPVVM0121"]}]},{"name":"Chang Gung Medical Foundation","award":["112F7MBOE1"],"award-info":[{"award-number":["112F7MBOE1"]}]},{"name":"Chang Gung Medical Foundation","award":["110F7MBME1"],"award-info":[{"award-number":["110F7MBME1"]}]},{"name":"Chang Gung Medical Foundation","award":["110F7MAIE1"],"award-info":[{"award-number":["110F7MAIE1"]}]},{"DOI":"10.13039\/501100005057","name":"Taiwan\u2019s National Tsing Hua University","doi-asserted-by":"publisher","award":["CMRPVVM0121"],"award-info":[{"award-number":["CMRPVVM0121"]}],"id":[{"id":"10.13039\/501100005057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005057","name":"Taiwan\u2019s National Tsing Hua University","doi-asserted-by":"publisher","award":["112F7MBOE1"],"award-info":[{"award-number":["112F7MBOE1"]}],"id":[{"id":"10.13039\/501100005057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005057","name":"Taiwan\u2019s National Tsing Hua University","doi-asserted-by":"publisher","award":["110F7MBME1"],"award-info":[{"award-number":["110F7MBME1"]}],"id":[{"id":"10.13039\/501100005057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005057","name":"Taiwan\u2019s National Tsing Hua University","doi-asserted-by":"publisher","award":["110F7MAIE1"],"award-info":[{"award-number":["110F7MAIE1"]}],"id":[{"id":"10.13039\/501100005057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>This study investigated miRNA and cytokine expression changes in peritoneal fluid samples of patients with advanced ovarian cancer (OVCA) after receiving hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreduction surgery (CRS). We collected samples prior to HIPEC, immediately after HIPEC, and 24\/48\/72 h after CRS from a total of 6 patients. Cytokine levels were assessed using a multiplex cytokine array, and a miRNA PanelChip Analysis System was used for miRNA detection. Following HIPEC, miR-320a-3p, and miR-663-a were found to be immediately down-regulated but increased after 24 h. Further, significant upregulation post-HIPEC and sustained increases in expression were detected in six other miRNAs, including miR-1290, miR-1972, miR-1254, miR-483-5p, miR-574-3p, and miR-574-5p. We also found significantly increased expression of cytokines, including MCP-1, IL-6, IL-6sR, TIMP-1, RANTES, and G-CSF. The changing expression pattern throughout the study duration included a negative correlation in miR-320a-3p and miR-663-a to cytokines including RANTES, TIMP-1, and IL-6 but a positive correlation in miRNAs to cytokines including MCP-1, IL-6sR, and G-CSF. Our study found miRNAs and cytokines in the peritoneal fluid of OVCA patients demonstrated different expression characteristics following CRS and HIPEC. Both changes in expression demonstrated correlations, but the role of HIPEC remains unknown, prompting the need for research in the future.<\/jats:p>","DOI":"10.3390\/ijms24119748","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T04:01:47Z","timestamp":1685937707000},"page":"9748","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Peritoneal Fluid Analysis of Advanced Ovarian Cancers after Hyperthermic Intraperitoneal Chemotherapy"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6515-0996","authenticated-orcid":false,"given":"Wei-Chun","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Department of Obstetrics and Gynecology, New Taipei City Municipal Tucheng Hospital, New Taipei City 236, Taiwan"},{"name":"International Intercollegiate Ph.D. Program & Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan"},{"name":"Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan"},{"name":"School of Traditional Chinese Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Chang","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-3280","authenticated-orcid":false,"given":"Hung-Hsueh","family":"Chou","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"School of Medicine, National Tsing Hua University, Hsinchu 300, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Hsiu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Taiwan Business Development Department, Inti Taiwan, Inc., Hsinchu 302, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Jie","family":"Hong","sequence":"additional","affiliation":[{"name":"Taiwan Business Development Department, Inti Taiwan, Inc., Hsinchu 302, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Shan","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Taiwan Business Development Department, Inti Taiwan, Inc., Hsinchu 302, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-1960","authenticated-orcid":false,"given":"Chao-Min","family":"Cheng","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/gyno.2002.6859","article-title":"Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer","volume":"88","author":"Havrilesky","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM199402033300508","article-title":"Care of patients with ascites","volume":"330","author":"Runyon","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_4","first-page":"1663","article-title":"The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma","volume":"32","author":"Feldman","year":"1972","journal-title":"Cancer Res."},{"key":"ref_5","first-page":"1579","article-title":"Angiogenic protein expression in advanced epithelial ovarian cancer","volume":"3","author":"Barton","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jnci\/90.6.447","article-title":"Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice","volume":"90","author":"Yoneda","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_7","first-page":"137","article-title":"Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy","volume":"63","author":"Loggie","year":"1997","journal-title":"Am. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdl499","article-title":"Pattern and prognostic factors in patients with malignant ascites: A retrospective study","volume":"18","author":"Ayantunde","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000010320","article-title":"The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female","volume":"50","author":"Sherer","year":"2000","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/cncr.20920","article-title":"The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma","volume":"103","author":"Eitan","year":"2005","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cncr.11618","article-title":"CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: Possible involvement of regulatory T cells in disease progression","volume":"98","author":"Sasada","year":"2003","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.18632\/oncotarget.6977","article-title":"Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites","volume":"7","author":"Lim","year":"2016","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1007\/s13277-015-4198-0","article-title":"The clinical significance of vascular endothelial growth factor in malignant ascites","volume":"37","author":"Zhan","year":"2016","journal-title":"Tumour Biol. J. Int. Soc. Oncodev. Biol. Med."},{"key":"ref_14","first-page":"881","article-title":"The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions","volume":"29","author":"Wada","year":"2009","journal-title":"Anticancer. Res."},{"key":"ref_15","first-page":"14","article-title":"Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-\u03baB and NFAT signaling in tumor-associated T cells","volume":"13","author":"Loyall","year":"2013","journal-title":"Cancer Immun."},{"key":"ref_16","first-page":"566","article-title":"Profiling of cytokines in human epithelial ovarian cancer ascites","volume":"2","author":"Matte","year":"2012","journal-title":"Am. J. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ygyno.2015.05.009","article-title":"Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-\u03b1 and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer","volume":"138","author":"Kolomeyevskaya","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chen, Y.L., Chang, M.C., Chen, C.A., Lin, H.W., Cheng, W.F., and Chien, C.L. (2012). Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047190"},{"key":"ref_19","first-page":"1","article-title":"Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients","volume":"13","author":"Wang","year":"2013","journal-title":"Cancer Immun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/ijc.28054","article-title":"Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion","volume":"133","author":"Han","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.molmed.2010.04.001","article-title":"Roles of small RNAs in tumor formation","volume":"16","author":"Croce","year":"2010","journal-title":"Trends Mol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.2147\/OTT.S137107","article-title":"miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples","volume":"10","author":"Braicu","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/07357907.2019.1663208","article-title":"Ovarian Cancer: Differentially Expressed microRNAs in Tumor Tissue and Cell-Free Ascitic Fluid as Potential Novel Biomarkers","volume":"37","author":"Weinberger","year":"2019","journal-title":"Cancer Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/IGC.0000000000000846","article-title":"A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer","volume":"27","author":"Zhu","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"De Cecco, L., Bagnoli, M., Chiodini, P., Pignata, S., and Mezzanzanica, D. (2021). Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets. Cancers, 13.","DOI":"10.3390\/cancers13071544"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bj.2021.10.003","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer","volume":"45","author":"Chen","year":"2022","journal-title":"Biomed. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0959-8049(98)00375-X","article-title":"Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment","volume":"35","author":"Berthet","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s002800051093","article-title":"Successful management of microscopic residual disease in large bowel cancer","volume":"43","author":"Sugarbaker","year":"1999","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e1535730","DOI":"10.1080\/2162402X.2018.1535730","article-title":"Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer","volume":"8","author":"Klynning","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/1078-0432.CCR-05-2516","article-title":"Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling","volume":"12","author":"Davidson","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.biocel.2010.01.014","article-title":"MicroRNAs in ovarian cancer biology and therapy resistance","volume":"42","author":"Helleman","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/emmm.201100209","article-title":"MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review","volume":"4","author":"Iorio","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tcb.2014.11.004","article-title":"The biological functions of miRNAs: Lessons from in vivo studies","volume":"25","author":"Vidigal","year":"2015","journal-title":"Trends Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.2147\/CMAR.S320834","article-title":"Identification and Functional Validation of Differentially Expressed microRNAs in Ascites-Derived Ovarian Cancer Cells Compared with Primary Tumour Tissue","volume":"13","author":"Jiang","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/1933719118776808","article-title":"Ascites-Derived Extracellular microRNAs as Potential Biomarkers for Ovarian Cancer","volume":"26","author":"Weinberger","year":"2019","journal-title":"Reprod. Sci. (Thousand oaks Calif.)"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"842","DOI":"10.4251\/wjgo.v11.i10.842","article-title":"MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation","volume":"11","author":"Li","year":"2019","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"645475","DOI":"10.3389\/fonc.2021.645475","article-title":"Circulating miR-320a Acts as a Tumor Suppressor and Prognostic Factor in Non-small Cell Lung Cancer","volume":"11","author":"Khandelwal","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1039\/D1BM01124C","article-title":"Delivery of miR-320a-3p by gold nanoparticles combined with photothermal therapy for directly targeting Sp1 in lung cancer","volume":"9","author":"Peng","year":"2021","journal-title":"Biomater. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/bjc.2013.795","article-title":"Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes","volume":"110","author":"Shapira","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9844","DOI":"10.12659\/MSM.916820","article-title":"Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972","volume":"25","author":"Guo","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41419-018-1262-x","article-title":"miR-1254 inhibits cell proliferation, migration, and invasion by down-regulating Smurf1 in gastric cancer","volume":"10","author":"Jiang","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1111\/jcmm.14981","article-title":"miR-1254 inhibits progression of glioma in vivo and in vitro by targeting CSF-1","volume":"24","author":"Li","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1177\/0960327121991912","article-title":"Quercetin suppresses cell survival and invasion in oral squamous cell carcinoma via the miR-1254\/CD36 cascade in vitro","volume":"40","author":"Chen","year":"2021","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8387458","DOI":"10.1155\/2022\/8387458","article-title":"LncRNA ABHD11-AS1 Participates in the Progression of Cervical Carcinoma by Targeting miR-1254 and Is the Key to the Diagnosis and Treatment of Cervical Carcinoma in the Future","volume":"2022","author":"Zhu","year":"2022","journal-title":"J. Healthc. Eng."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"771","DOI":"10.7150\/jca.49680","article-title":"Upregulation of miR-1254 promotes Hepatocellular Carcinoma Cell Proliferation, Migration, and Invasion via Inactivation of the Hippo-YAP signaling pathway by decreasing PAX5","volume":"12","author":"Lu","year":"2021","journal-title":"J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1158\/0008-5472.CAN-13-2193","article-title":"miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM","volume":"74","author":"Song","year":"2014","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3892\/etm.2021.10480","article-title":"Inhibition of miR-483-5p improves the proliferation, invasion and inflammatory response of triple-negative breast cancer cells by targeting SOCS3","volume":"22","author":"Ren","year":"2021","journal-title":"Exp. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Chiyomaru, T., Yamamura, S., Fukuhara, S., Hidaka, H., Majid, S., Saini, S., Arora, S., Deng, G., Shahryari, V., and Chang, I. (2013). Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058929"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00210-019-01772-6","article-title":"Inhibition of miR-574-5p suppresses cell growth and metastasis and enhances chemosensitivity by targeting RNA binding protein QKI in cervical cancer cells","volume":"393","author":"Tong","year":"2020","journal-title":"Naunyn Schmiedebergs Arch. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Michaille, J.J., Piurowski, V., Rigot, B., Kelani, H., Fortman, E.C., and Tili, E. (2018). MiR-663, a MicroRNA Linked with Inflammation and Cancer That Is under the Influence of Resveratrol. Medicines, 5.","DOI":"10.3390\/medicines5030074"},{"key":"ref_53","first-page":"105","article-title":"Tumor-suppressive mir-663 gene induces mitotic catastrophe growth arrest in human gastric cancer cells","volume":"24","author":"Pan","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_54","first-page":"293","article-title":"Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells","volume":"8","author":"Kim","year":"2014","journal-title":"Drug. Des. Devel"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40659-019-0219-6","article-title":"MicroRNA-663 facilitates the growth, migration and invasion of ovarian cancer cell by inhibiting TUSC2","volume":"52","author":"Xie","year":"2019","journal-title":"Biol. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2741\/e237","article-title":"Relationship between RANTES and dendritic cells in ovarian cancer patients","volume":"3","author":"Wertel","year":"2011","journal-title":"Front. Biosci. (Elite Ed)"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ygyno.2006.01.029","article-title":"Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder","volume":"102","author":"Tsukishiro","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_58","first-page":"1093","article-title":"The CC chemokine RANTES in breast carcinoma progression: Regulation of expression and potential mechanisms of promalignant activity","volume":"62","author":"Azenshtein","year":"2002","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"17543","DOI":"10.18632\/oncotarget.24784","article-title":"RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells","volume":"9","author":"Gallo","year":"2018","journal-title":"Oncotarget"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/bjc.2013.673","article-title":"Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2\/signal transducer and activator of transcription 3 in ovarian cancer","volume":"110","author":"Kumar","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc.2016.115","article-title":"TIMPs: Versatile extracellular regulators in cancer","volume":"17","author":"Jackson","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Gong, Y., Scott, E., Lu, R., Xu, Y., Oh, W.K., and Yu, Q. (2013). TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077366"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12943-016-0515-5","article-title":"Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer","volume":"15","author":"Cheng","year":"2016","journal-title":"Mol. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Steffensen, K.D., Waldstr\u00f8m, M., Christensen, R.K., Bartels, A., Br\u00fcnner, N., and Jakobsen, A. (2010). Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-185"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/s41388-019-1090-1","article-title":"MCP-1\/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis","volume":"39","author":"Sun","year":"2020","journal-title":"Oncogene"},{"key":"ref_66","first-page":"4785","article-title":"MCP-1 promotes invasion and adhesion of human ovarian cancer cells","volume":"33","author":"Furukawa","year":"2013","journal-title":"Anticancer. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/IGC.0b013e3181e5c442","article-title":"Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer","volume":"20","author":"Geller","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0022-5347(05)65348-7","article-title":"Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer","volume":"167","author":"Andrews","year":"2002","journal-title":"J. Urol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00262-021-02953-0","article-title":"Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer","volume":"71","author":"Schuettfort","year":"2022","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/jcmm.12483","article-title":"MiR-320a contributes to atherogenesis by augmenting multiple risk factors and down-regulating SRF","volume":"19","author":"Chen","year":"2015","journal-title":"J. Cell Mol. Med."},{"key":"ref_71","first-page":"3796","article-title":"MiR-663a\/MiR-423-5p are involved in the pathogenesis of lupus nephritis via modulating the activation of NF-\u03baB by targeting TNIP2","volume":"9","author":"Wang","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"ref_72","unstructured":"RayBiotech (2021, September 11). Homepage of RayBiotech Company. Available online: https:\/\/www.raybiotech.com\/."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Fraley, E., LeMaster, C., Geanes, E., Banerjee, D., Khanal, S., Grundberg, E., Selvarangan, R., and Bradley, T. (2021). Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals. BMC Med., 19.","DOI":"10.1186\/s12916-021-02055-9"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9748\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:48:21Z","timestamp":1760125701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":73,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms24119748"],"URL":"https:\/\/doi.org\/10.3390\/ijms24119748","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]}}}